Citatuzumab bogatox

N/A

Report date: 2022/11/25 17:01:02

Base Information

Drug NameCitatuzumab bogatox
Drug Alias Name泊西他珠单抗VB6-845VB6-845d
ClassificationBiologics > Protein drugs > Toxin
Mechanisms of ActionEpithelial cell adhesion molecule modulatorsRibosome inhibitors
TargetsEpithelial cell adhesion molecule
Therapy Area/IndicationsNeoplasms, Glandular and Epithelial
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryRussian FederationGeorgia
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesViventia Biotech Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSesen Bio Inc
Active IndicationsN/A
Inactive IndicationsNeoplasms, Glandular and Epithelial

Other Information

ATC CodeN/A
Related LinksWikipedia